Trial · NCT02930655
A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
NCT02930655, Phase 1, Completed, Idorsia Pharmaceuticals Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease. Trials, record NCT02930655. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02930655
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
- NCT number
- NCT02930655
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 14 participants, actual
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Conditions
- Fabry Disease
- Interventions
- Lucerastat, Enzyme replacement therapy (ERT)
- First posted
- 2016-10-12
- Last updated
- 2018-07-10
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in blood pressure | Up to Week 12 | |
| Primary | Change from baseline in heart rate | Up to Week 12 | |
| Primary | Change from baseline in electrocardiogram (ECG) variables | Up to Week 12 | The duration (in ms) of the different ECG variables were measured using a standard 12-lead ECG |
| Primary | Change from baseline in body weight | Up to Week 12 | |
| Primary | Number of subjects with treatment-emergent adverse events and serious adverse events | Up to Week 12 | |
| Primary | Number of subjects with adverse events leading to premature discontinuation of lucerastat or ERT | Up to Week 12 | |
| Primary | Number of subjects with treatment-emergent abnormalities in laboratory variables | Up to Week 12 | |
| Secondary | Change from baseline in plasma biomarkers of Fabry Disease | Up to Week 12 | Biomarkers reflecting glycolipid metabolism were measured (unit of measure: ng/mL) |
| Secondary | Change from baseline in urine biomarker of Fabry Disease | Up to Week 12 | Biomarker reflecting glycolipid metabolism was measured (unit of measure: ng/mg) |
| Secondary | Change from baseline in left ventricular ejection fraction (LVEF) | Up to Week 12 | LVEF was used to monitor cardiac function in subjects with Fabry Disease |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28088251 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02930655
GET https://conductscience.org/api/trials/v1/NCT02930655/registered